Holding(s) in Company

RNS Number : 0854V
Allergy Therapeutics PLC
03 July 2009
 






TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES


1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

  

 

ALLERGY THERAPEUTICS PLC

 


2 Reason for the notification (please tick the appropriate box or boxes):


An acquisition or disposal of voting rights

 


An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 


An event changing the breakdown of voting rights

 X


Other (please specify):

  

 


3. Full name of person(s) subject to the notification obligation:


 M&G INVESTMENT FUNDS 3

 

4. Full name of shareholder(s) (if different from 3.):


NORTRUST NOMINEE LTD A/C MKM01

 

5. Date of the transaction and date on which the threshold is crossed or reached:


 

01 JULY 2009

 

6. Date on which issuer notified:


 02 JULY 2009

 

7. Threshold(s) that is/are crossed or reached:


9% TO 2%

 

  

8. Notified details:

A: Voting rights attached to shares


Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the 
triggering
transaction

Resulting situation after the triggering transaction

Number
of

Shares

Number
of

V
oting
Rights

Number
of shares

Number of voting
rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

 ORD GBP0.001

GB00B02LCQ05

 

7,500,000

 

7,500,000

 

7,500,000

 

7,500,000 

 

 

2.84%

 

 


B: Qualifying Financial Instruments

Resulting situation after the triggering transaction


Type of financial
instrument

Expiration
date

Exercise/ 
Conversion 
Period

Number of voting
rights that may be

acquired if the

instrument is

exercised/ converted.


% of voting
rights

 

 

 

 

 


C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction


Type of financial
instrument

Exercise 
price

Expiration 
date

Exercise/
Conversion 

period

Number of voting 
rights instrument 
refers to

% of voting rights


 

 

 

 

 

Nominal

Delta


 

 


Total (A+B+C)


Number of voting rights

Percentage of voting rights

 

BELOW 5% 

 

BELOW 5%


9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

 


Proxy Voting:


10. Name of the proxy holder:


 N/A

 

11. Number of voting rights proxy holder will cease to hold:


N/A

 

12. Date on which proxy holder will cease to hold voting rights:


N/A 


13. Additional information:


With reference to item 3, M&G Investments Funds 3 is an  Open Ended Investment Company (OEIC) and is not a Prudential group company and must be separately disclosed.

 

This OEIC Fund is managed by M&G Investment Management Limited (a wholly owned subsidiary of Prudential plc) and will have been previously attributed to Prudential plc solely on the basis that M&G Investment Management Ltd has direct fund management control over the shares identified in this notification.

Therefore the 2.84% holding being disclosed in this notification is emcompassed in the 5.68% already disclosed under The Prudential plc group of companies and is NOT in addition to it.

 

Calculations based on a Total Voting Rights figure of 263,998,551.

 

14. Contact name:


DIPESH VARSANI / MARK THOMAS

M&G INVESTMENT MANAGEMENT LIMITED

 

15. Contact telephone number:


020 7548 3261/020 7548 3266 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOVKRKNRBRRR
UK 100

Latest directors dealings